Therapy Goals in IBD: How good is good enough?

During the 9^th Swiss IBD Roadshow supported by AbbVie, Prof. Dr. med. Axel Dignass, Agaplesion Markus Hospital, Goethe University in Frankfurt am Main, discussed the new STRIDE II recommendations for the treatment of Crohn’s Disease and Ulcerative Colitis and talked about current therapeutic goals and strategies. Please watch the highlights of his presentation in the following video!

In May 2022, Prof. Dr. med. Axel Dignass visited seven locations all over Switzerland to discuss the new STRIDE II recommendations with the local audience [1].

Highlights of Prof. Dr. med. Axel Dignass’s talk during the 37^th IBD Forum in Zurich, May 10^th, 2022

Please also read the extensive interview with Prof. Dr. med. Axel Dignass in German or French !

References

1. Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021. 160(5): p. 1570-1583.

References can be requested by medical professionals via medinfo.ch@abbvie.com

Humira® (Deutsch)

Humira® (Français)

Financially supported by AbbVie AG, Alte Steinhauserstrasse 14, 6330 Cham.

Dr. sc. nat. Jennifer Keim

CH-HUMG-220078_09/2022

Article online since 13.10.2022